Roles of activin receptor-like kinase 7 signaling and its target, peroxisome proliferator-activated receptor., in lean and obese adipocytes

被引:13
|
作者
Yogosawa, Satomi [1 ]
Izumi, Tetsuro [1 ]
机构
[1] Gunma Univ, Inst Mol & Cellular Regulati, Dept Mol Med, Lab Mol Endocrinol & Metabolism, Gunma, Japan
关键词
triglyceride synthesis; lipolysis; adipocyte size; obesity; PPAR gamma agonist;
D O I
10.4161/adip.24974
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We recently discovered a novel signaling pathway involving activin receptor-like kinase 7 (ALK7), one of the type I transforming growth factor-beta receptors. ALK7 and activated Smads 2, 3, and 4 inhibit the master regulators of adipogenesis, CCAAT/enhancer-binding protein a (C/EBP alpha) and peroxisome proliferator-activated receptor (PPAR gamma) specifically in differentiated adipocytes, but surprisingly increase both the adipocyte size and lipid content by suppressing lipolysis. Here, we show that, although both transcription factors are suppressed by ALK7 in either the obese or lean state, PPAR gamma, but not C/EBPa, is further suppressed under obesity through an ALK7-independent pathway. As a result, PP AR. and adipose lipolytic activities are severely downregulated in obesity. Reactivation of PPAR gamma by ALK7 inactivation leads to downregulation of inflammatory adipocytokines and upregulation of adiponectin. We propose that PPAR gamma promotes lipid turnover and remodeling by stimulating both triglyceride synthesis and breakdown in differentiated adipocytes. Finally, we discuss the physiological and evolutionary roles of the ALK7-signaling pathway and consider it as a potential target of therapy for obesity.
引用
收藏
页码:246 / 250
页数:5
相关论文
共 50 条
  • [21] Peroxisome proliferator-activated receptor β/δ as a therapeutic target for metabolic diseases
    Bedu, E
    Wahli, W
    Desvergne, A
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2005, 9 (04) : 861 - 873
  • [22] Peroxisome proliferator-activated receptor β/δ:: A new antihypertrophic drug target?
    Petrashevskaya, NN
    Schwarz, A
    CARDIOVASCULAR RESEARCH, 2005, 65 (04) : 770 - 771
  • [23] Regulation of peroxisome proliferator-activated receptor α by protein kinase C
    Gray, JP
    Burns, KA
    Leas, TL
    Perdew, GH
    Heuvel, JPV
    BIOCHEMISTRY, 2005, 44 (30) : 10313 - 10321
  • [24] Peroxisome proliferator-activated receptor γ:: a novel target for cancer therapeutics?
    Han, ShouWei
    Roman, Jesse
    ANTI-CANCER DRUGS, 2007, 18 (03) : 237 - 244
  • [25] Peroxisome proliferator-activated receptor γ as a novel therapeutic target in asthma
    Park, Seoung Ju
    Lee, Yong Chul
    JOURNAL OF ASTHMA, 2008, 45 (01) : 1 - 8
  • [26] Diclofenac antagonizes peroxisome proliferator-activated receptor-γ signaling
    Adamson, DJA
    Frew, D
    Tatoud, R
    Wolf, CR
    Palmer, CNA
    MOLECULAR PHARMACOLOGY, 2002, 61 (01) : 7 - 12
  • [27] The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling
    Shi, YH
    Hon, M
    Evans, RM
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (05) : 2613 - 2618
  • [28] Relaxin signaling activates peroxisome proliferator-activated receptor gamma
    Singh, Sudhir
    Bennett, Robert G.
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2010, 315 (1-2) : 239 - 245
  • [29] Expression of peroxisome proliferator-activated receptor-γ1 and peroxisome proliferator-activated receptor-γ2 in visceral and subcutaneous adipose tissue of obese women
    Giusti, V
    Verdumo, C
    Suter, M
    Gaillard, RC
    Burckhardt, P
    Pralong, F
    DIABETES, 2003, 52 (07) : 1673 - 1676
  • [30] Missense variants in the human peroxisome proliferator-activated receptor-γ2 gene in lean and obese subjects
    Hamann, A
    Münzberg, H
    Buttron, P
    Büsing, B
    Hinney, A
    Mayer, H
    Siegfried, W
    Hebebrand, J
    Greten, H
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1999, 141 (01) : 90 - 92